TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.
Mantle Cell Lymphoma
DRUG: 400mg of TQB3909 tablets|DRUG: 600mg of TQB3909 tablets
Recommended phase II dose (RP2D), Recommended phase II dose (RP2D), Baseline up to 48-weeks
The incidence of adverse events (AEs), Number of participants with adverse events (AE) and/or severe adverse events (SAE) and/or abnormal laboratory examination indicators., Baseline up to 96-weeks|The severity of adverse events (AEs), The severity of adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0., Baseline up to 96-weeks|The severity of severe adverse events (SAEs), The severity of severe adverse events (SAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0., Baseline up to 96-weeks|The severity of abnormal laboratory examination indicators, The severity of abnormal laboratory examination indicators as assessed by Common Terminology Criteria for Adverse Events (CTCAE) 5.0., Baseline up to 96-weeks
This is a study to assess the safety of TQB3909 monotherapy in participants with relapsed or refractory MCL.